Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

1,098

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

August 30, 2018

Study Completion Date

October 8, 2018

Conditions
Schizophrenia
Interventions
DRUG

Risperidone

4-6 mg/day, encapsulated tablets, orally

DRUG

Olanzapine

15-20 mg/day, encapsulated tablets, orally

DRUG

Lu AF35700

10 mg/day, encapsulated tablets, orally

DRUG

Lu AF35700

20 mg/day, encapsulated tablets, orally

Trial Locations (147)

10032

US1394, New York

10312

US1190, Staten Island

11004

US1405, Glen Oaks

11432

US1244, Jamaica

14618

US1171, Rochester

19403

US1124, Norristown

20016

US1396, Washington D.C.

29407

US1319, Charleston

30030

US1442, Decatur

30328

US1403, Atlanta

30331

US1009, Atlanta

32256

US1253, Jacksonville

32751

US1395, Bradenton

32763

US1229, Orange City

33122

US1130, Miami

33161

US1318, North Miami

33162

US1129, North Miami

39232

US1086, Flowood

60640

US1046, Chicago

75243

US1065, Dallas

76104

US1443, Fort Worth

90230

US1463, Culver City

90703

US1041, Cerritos

90706

US1018, Bellflower

91206

US1118, Glendale

91945

US1399, Orange

91950

US1114, National City

92626

US1062, Costa Mesa

92845

US1104, Garden Grove

92868

US1368, Orange

92056-4509

US1452, Oceanside

92056-4515

US1459, Oceanside

92408-3332

US1391, San Bernardino

92705-3610

US1464, Santa Ana

91403-1747

US1384, Sherman Oaks

90502-4432

US1392, Torrance

33334-4400

US1402, Oakland Park

33609-2231

US1453, Tampa

60169-1067

US1423, Hoffman Estates

71101-4603

US1398, Shreveport

71104-2136

US1404, Shreveport

89102-1943

US1444, Las Vegas

08009

US1426, Berlin

08053

US1454, Marlton

10035-6000

US1416, New York

28204-3110

US1390, Charlotte

28211-1064

US1401, Charlotte

28601-5045

US1441, Hickory

78754-5122

US1451, Austin

Unknown

BG1030, Burgas

BG1028, Kazanlak

BG1003, Lovech

BG1032, Pazardzhik

BG1008, Plovdiv

BG1024, Sofia

BG1026, Sofia

BG1022, Tserova Koria

BG1033, Varna

BG1034, Varna

BG1029, Veliko Tarnovo

BG1027, Vratsa

CA1017, Chatham

CA1034, Kingston

CA1003, Montreal

CA1033, Montreal

CA1029, Penticton

CA1039, Québec

CZ1023, Brno

CZ1032, Brno

CZ1037, Hostivice

CZ1013, Lnáře

CZ1038, Prague

EE1016, Pärnu

EE1007, Tallinn

EE1017, Viljandi

FI1032, Espoo

FI1030, Kuopio

FI1027, Turku

MX1024, Durango

MX1011, Guadalajara

MX1021, Guadalajara

MX1022, Guadalajara

MX1020, México

MX1005, Monterrey

MX1007, Monterrey

MX1015, Monterrey

MX1016, Monterrey

MX1018, San Luis Potosí City

PL1025, Bełchatów

PL1043, Bialystok

PL1026, Gorlice

PL1060, Lodz

PL1027, Lublin

PL1058, Pruszcz Gdański

PL1061, Pruszków

PL1059, Torun

PL1051, Wroclaw

RO1024, Bucharest

RO1022, Campulung Muscel

RO1025, Sibiu

RO1004, Târgu Mureş

RU1021, Nikol’skoye

RU1009, Arkhangelsk

RU1006, Moscow

RU1051, Moscow

RU1055, Moscow

RU1023, Saint Petersburg

RU1028, Saint Petersburg

RU1030, Saint Petersburg

RU1031, Saint Petersburg

RU1049, Saint Petersburg

RU1052, Saint Petersburg

RU1053, Saint Petersburg

RU1056, Saint Petersburg

RU1050, Yaroslavl

RS1008, Belgrade

RS1010, Belgrade

RS1012, Belgrade

RS1011, Kragujevac

RS1016, Kragujevac

RS1017, Kragujevac

RS1003, Niš

RS1009, Novi Kneževac

SK1014, Bratislava

SK1024, Bratislava

SK1015, Rožňava

SK1025, Svidník

SK1026, Zlaté Moravce

ES1047, Barcelona

ES1012, Madrid

ES1008, Málaga

ES1048, Oviedo

ES1049, Zamora

UA1019, Dnipropetrovsk

UA1017, Kharkiv

UA1022, Kharkiv

UA1031, Kharkiv

UA1035, Kharkiv

UA1028, Kherson

UA1029, Kherson

UA1027, Kiev

UA1030, Kiev

UA1033, Lviv

UA1020, Odesa

UA1032, Odesa

UA1001, Poltava

UA1036, Vinnitsa

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT02717195 - Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia | Biotech Hunter | Biotech Hunter